Holen Sie sich die Stockscreener-App
1.63
16.84%
-0.33
Handel nachbörslich:
1.65
0.02
+1.23%
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
PYXS: MICVO demonstrates high efficacy and improved safety in head and neck cancer with dose capping - TradingView
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $6 - Moomoo
RBC Capital Keeps Their Buy Rating on Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology (PYXS) Gets a Buy from Guggenheim - The Globe and Mail
Wedbush Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - Moomoo
Pyxis Oncology (PYXS) Cash Runway Under One Year Reinforces Bearish Funding Narratives - Sahm
Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility - TipRanks
Pyxis Oncology, Inc. Faces Substantial Doubt as a Going Concern and Requires Additional Capital – 2026 Q1 Financial Report Highlights Risks and Challenges 25 - Minichart
Pyxis Oncology Shares Slide on Steeper 1Q Loss - Moomoo
Pyxis Oncology Reports Q1 2026 Financial Results and Advances MICVO ADC Toward Key Clinical Milestones in Head and Neck Cancer - Minichart
Pyxis Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pyxis Oncology stock (US70611B1026): Q1 2026 loss widens to $23.3M - AD HOC NEWS
Pyxis Oncology (PYXS) Q1 2026 loss deepens as MICVO trials expand and cash runway tightens - Stock Titan
Pyxis Oncology (PYXS) posts $23.3M Q1 loss and advances MICVO trials - Stock Titan
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - marketscreener.com
BRIEF-Pyxis Oncology Q1 Net Income USD -23.272 Million - TradingView
Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Should You Sell Pyxis Oncology (PYXS) After -18.89% Drop? 2026-05-14Viral Trades - newser.com
Pyxis Oncology to Participate in Upcoming Investor Conferences - Caledonian Record
Cancer drug developer Pyxis Oncology plans investor webcasts - Stock Titan
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - MSN
Pyxis Oncology stock (US70611B1026): Builds $540M cash pile after Q1 loss - AD HOC NEWS
Pyxis Oncology Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer - The Manila Times
SEC EDGAR Submission 0000950170-23-023950 - SEC.gov
Pyxis brings in former ImmunoGen dealmaker to advance MICVO - Stock Titan
Pyxis Oncology, Inc. Appoints Nelson Azoulay as Chief Business Officer - marketscreener.com
Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target - marketscreener.com
Wedbush initiated coverage on Pyxis Oncology with a new price target - Quantisnow
Wedbush Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $6 - Moomoo
Pyxis Oncology (PYXS) Price Target Increased by 13.33% to 6.94 - MSN
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7% - MarketBeat
Pyxis Oncology, Inc. Files Amended 8-K/A Report for 2026 with SEC – Company Details, Address, and Nasdaq Listing - Minichart
Pyxis Oncology (PYXS) Management Strategy | Pyxis Oncology posts 15.6% EPS beat, no revenueDebt Analysis - newser.com
[ARS] Pyxis Oncology, Inc. SEC Filing - Stock Titan
Pyxis Oncology | DEFA14A: Others - Moomoo
Pyxis Oncology (NASDAQ: PYXS) details 2026 vote on directors and auditor - Stock Titan
Pyxis Oncology | 8-K/A: Current report (Amendment) - Moomoo
Lara Sullivan exit package at Pyxis Oncology (NASDAQ: PYXS) - Stock Titan
Pyxis Oncology, Inc. Announces Resignation of Lara Sullivan from the Board of Directors, Effective April 29, 2026 - marketscreener.com
PYXS Pyxis Oncology beats Q4 2025 loss estimates, but shares shed 2.35 percent amid weak investor reaction.EBIT Margin - Newser
PYXS Pyxis Oncology Q4 2025 narrower than expected per share loss sparks double digit share price jump today.Community Driven Stock Picks - newser.com
PYXS Stock: Analyzing Pyxis Oncology's Market Performance - Bitget
Pyxis Oncology (PYXS) Cantor Global Healthcare Conference 2025 Summary - Quartr
Pyxis Oncology (PYXS) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
Pyxis Oncology (PYXS) Registration Filing Summary - Quartr
Pyxis Oncology (PYXS) H.C. Wainwright 26th Annual Global Investment Conference summary - Quartr
Pyxis Oncology (PYXS) Proxy Filing Summary - Quartr
Pyxis Oncology (PYXS) Leerink Global Healthcare Conference 2025 Summary - Quartr
Stifel Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 - The Manila Times
Pyxis presents preclinical data on MICVO in head and neck cancer - Investing.com Australia
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):